Lenti-CD276 CAR (scFv-28ζ, CD276.1)-VP(VP-CAR-LC645)

The ready-to-use lentiviral particles of Lenti-CD276 CAR (scFv-28ζ, CD276.1)-VP is packaged using 3rd generation of lentiviral packaging system, in which the gene of CAR will be driven by a CMV promotor. The target gene of scFv (CD276.1)-CD28-CD3ζ packaged in lentiviral particles could be used for high efficency tranduction of T cells and stably integrated expression.


Specifications


Type of Therapeutics
Chimeric Antigen Receptor
Target
CD276
Expression Cassette
scFv (CD276.1)-CD28-CD3ζ
Clone
CD276.1
Promotor
CMV
Packaging System
Lentivirus
Packaging Cell
293T
Targeting Diseases
Ovarian cancer, Breast cancer

Target


Introduction
CD276 (CD276 Molecule) is a Protein Coding gene. Diseases associated with CD276 include Neuroblastoma and Acute Cervicitis. Among its related pathways are T Cell Co-Signaling Pathway: Ligand-Receptor Interactions and NF-kappaB Signaling. Gene Ontology (GO) annotations related to this gene include receptor binding. An important paralog of this gene is LOC102723996.
Alternative Names
CD276 Molecule; CD276 Antigen; Costimulatory Molecule; B7 Homolog 3; 4Ig-B7-H3; B7-H3; B7H3; B7RP-2;
Gene ID

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products


Others Kits for CARs/TCRs Development 

Online Inquiry

Name:
* Phone:
*E-mail Address:
*Service & Products Interested:
Project Description:
*Verification Code:
Please input "biolabs"(case insensitive) as verification code.
CB Promise
CONTACT US
45-1 Ramsey Road, Shirley, NY 11967, USA
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356
Email:
CONTACT US

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email:

Europe
Tel: 44-207-097-1828

Distributors

To view the contact information for a specific location, select your country or region:

Australia
australia

FOLLOW US ON